Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 387

1.

The diagnostic role of claudins in serous effusions.

Kleinberg L, Holth A, Fridman E, Schwartz I, Shih IeM, Davidson B.

Am J Clin Pathol. 2007 Jun;127(6):928-37.

PMID:
17509990
[PubMed - indexed for MEDLINE]
Free Article
2.

D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.

Bassarova AV, Nesland JM, Davidson B.

Am J Surg Pathol. 2006 Jul;30(7):878-82.

PMID:
16819331
[PubMed - indexed for MEDLINE]
3.

Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.

Afify AM, Stern R, Michael CW.

Diagn Cytopathol. 2005 Mar;32(3):145-50.

PMID:
15690337
[PubMed - indexed for MEDLINE]
4.

Diagnostic utility of thyroid transcription factor-1 expression in adenocarcinomas presenting in serous fluids.

Afify AM, al-Khafaji BM.

Acta Cytol. 2002 Jul-Aug;46(4):675-8.

PMID:
12146029
[PubMed - indexed for MEDLINE]
5.

Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions.

Slipicevic A, Øy GF, Askildt IC, Holth A, Hellesylt E, Flørenes VA, Davidson B.

Hum Pathol. 2009 Apr;40(4):527-37. doi: 10.1016/j.humpath.2008.10.003. Epub 2009 Jan 3.

PMID:
19121847
[PubMed - indexed for MEDLINE]
6.

Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids.

Afify A, Zhou H, Howell L, Paulino AF.

Acta Cytol. 2005 Nov-Dec;49(6):621-6.

PMID:
16450901
[PubMed - indexed for MEDLINE]
7.
8.

[Determining the primary site of metastatic adenocarcinoma in serous fluid: a cytological study].

Fang F, Yang L, Su XL, He Q, Liu DG, Lin FR, Ma ZZ.

Zhonghua Bing Li Xue Za Zhi. 2005 Oct;34(10):641-5. Chinese.

PMID:
16536276
[PubMed - indexed for MEDLINE]
9.

IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.

Ikeda K, Tate G, Suzuki T, Kitamura T, Mitsuya T.

Hum Pathol. 2010 May;41(5):745-50. doi: 10.1016/j.humpath.2009.04.030. Epub 2010 Jan 13.

PMID:
20060157
[PubMed - indexed for MEDLINE]
10.

Kallikrein 4 is expressed in malignant mesothelioma--further evidence for the histogenetic link between mesothelial and epithelial cells.

Davidson B, Xi Z, Saatcioglu F.

Diagn Cytopathol. 2007 Feb;35(2):80-4.

PMID:
17230566
[PubMed - indexed for MEDLINE]
11.

Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities.

Reich R, Vintman L, Nielsen S, Kaern J, Bedrossian C, Berner A, Davidson B.

Diagn Cytopathol. 2005 Nov;33(5):332-7.

PMID:
16240397
[PubMed - indexed for MEDLINE]
12.
13.

Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.

Su XY, Li GD, Liu WP, Xie B, Jiang YH.

Diagn Cytopathol. 2011 Dec;39(12):900-8. doi: 10.1002/dc.21489. Epub 2010 Sep 10.

PMID:
20836004
[PubMed - indexed for MEDLINE]
14.

MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells.

Davidson B, Baekelandt M, Shih IeM.

Diagn Cytopathol. 2007 Dec;35(12):756-60.

PMID:
18008338
[PubMed - indexed for MEDLINE]
15.

CK5/6 in effusions: no difference between mesothelioma and pulmonary and nonpulmonary adenocarcinoma.

Dejmek A.

Acta Cytol. 2008 Sep-Oct;52(5):579-83.

PMID:
18833821
[PubMed - indexed for MEDLINE]
16.

Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma.

Delahaye M, Hoogsteden HC, Van der Kwast TH.

J Pathol. 1991 Oct;165(2):137-43.

PMID:
1744800
[PubMed - indexed for MEDLINE]
17.

Podoplanin is a useful marker for identifying mesothelioma in malignant effusions.

Hanna A, Pang Y, Bedrossian CW, Dejmek A, Michael CW.

Diagn Cytopathol. 2010 Apr;38(4):264-9. doi: 10.1002/dc.21340.

PMID:
20146302
[PubMed - indexed for MEDLINE]
18.

WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids.

Lee BH, Hecht JL, Pinkus JL, Pinkus GS.

Am J Clin Pathol. 2002 May;117(5):745-50.

PMID:
12090423
[PubMed - indexed for MEDLINE]
Free Article
19.

Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions.

Yuan Y, Nymoen DA, Dong HP, Bjørang O, Shih IeM, Low PS, Trope' CG, Davidson B.

Hum Pathol. 2009 Oct;40(10):1453-60. doi: 10.1016/j.humpath.2009.02.013. Epub 2009 May 19.

PMID:
19454358
[PubMed - indexed for MEDLINE]
20.

Usefulness of Claudin 4 in the cytological diagnosis of serosal effusions.

Lonardi S, Manera C, Marucci R, Santoro A, Lorenzi L, Facchetti F.

Diagn Cytopathol. 2011 May;39(5):313-7. doi: 10.1002/dc.21380.

PMID:
21488172
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk